Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?

Imagem de Miniatura
Citações na Scopus
Tipo de produção
Data de publicação
Título da Revista
ISSN da Revista
Título do Volume
NUCCI, Marcio
SHOHAM, Shmuel
RICO, Juan Carlos
NOUER, Simone A.
SOLZA, Cristiana
MYCOSES, v.62, n.5, p.413-417, 2019
Projetos de Pesquisa
Unidades Organizacionais
Background Patients treated for invasive aspergillosis may relapse during subsequent periods of immunosuppression and should receive secondary prophylaxis. Little is known about the frequency of relapse and practices of secondary prophylaxis for invasive fusariosis (IF). Objectives Evaluate practices of secondary prophylaxis and the frequency of relapse in patients who survived IF and were exposed to subsequent periods of immunosuppression. Methods Multicentre retrospective study of patients with haematological malignancies who developed IF, survived the initial fungal disease period, and were exposed to subsequent periods of immunosuppression. Results Among 40 patients, 35 received additional chemotherapy and developed neutropenia (median, 24 days; range, 4-104), and five received glucocorticoids for the treatment of graft-vs-host disease. Overall, 32 patients received secondary prophylaxis (voriconazole in 24) for a median of 112 days (range, 12-468). IF relapsed in five patients (12.5%): 2/8 (25%) not on prophylaxis and 3/32 (9.4%) receiving prophylaxis. Among 28 patients with disseminated IF, relapse occurred in 2/2 (100%) not on prophylaxis and in 3/26 (11.5%) on prophylaxis (P = 0.03). All patients who relapsed IF died. Conclusions Patients with IF who survive the initial disease may relapse if exposed to subsequent episodes of immunosuppressive therapies. Secondary prophylaxis should be considered, especially if IF was disseminated.
fusariosis, Fusarium, prophylaxis, relapse, secondary prophylaxis
  1. Cordonnier C, 2004, BONE MARROW TRANSPL, V33, P943, DOI 10.1038/sj.bmt.1704469
  2. Cornely OA, 2014, CLIN MICROBIOL INFEC, V20, P5, DOI 10.1111/1469-0691.12371
  3. De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660
  4. Fukuda T, 2004, BIOL BLOOD MARROW TR, V10, P494, DOI 10.1016/j.bbmt.2004.02.006
  5. Martino R, 2006, BLOOD, V108, P2928, DOI 10.1182/blood-2006-03-008706
  6. Nucci M, 2014, CLIN MICROBIOL INFEC, V20, P580, DOI 10.1111/1469-0691.12409
  7. Nucci M, 2003, CANCER, V98, P315, DOI 10.1002/cncr.11510
  8. Nucci M, 2007, CLIN MICROBIOL REV, V20, P695, DOI 10.1128/CMR.00014-07
  9. Patterson TF, 2016, CLIN INFECT DIS, V63, pE1, DOI 10.1093/cid/ciw326
  10. Sipsas NV, 2006, CLIN INFECT DIS, V42, P1584, DOI 10.1086/503844
  11. Tortorano AM, 2014, CLIN MICROBIOL INFEC, V20, P27, DOI 10.1111/1469-0691.12465
  12. VELASCO E, 1995, EUR J CLIN MICROBIOL, V14, P697, DOI 10.1007/BF01690877